European stakeholder learnings regarding biosimilars: Part I – improving biosimilar understanding and adoption

BioDrugs

Liese Barbier[1*], Steven Simoens[1], Arnold G. Vulto[1,2+*], Isabelle Huys[1+]

[1]KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium
[2]Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, the Netherlands

[+] Joint last author: these authors contributed equally to this work

[*] Corresponding author:

Arnold G. Vulto Contact: a.vulto@gmail.com

Liese Barbier Contact: liese.barbier@kuleuven.be

Online Resource 5. Participant's characteristics – I

Participants' characteristics			
Stakeholder	**n=44**	**Country**	**Therapeutic area**
Hospital pharmacist	10	Austria (1) Belgium (2) Croatia (1) EU perspective (2)* France (1) Spain (1) The Netherlands (2)	Non-disease specific (10)
Physician	9	Belgium (1) EU perspective (2)* Italy (1) Spain (2) The Netherlands (2) UK (1)	Endocrinology (1) Gastroenterology (3) Nephrology (1) Oncology (3) Rheumatology (1)
Nurse	9	Belgium (2) Denmark (1) EU perspective (1)* Malta (1) The Netherlands (3) Switzerland (1)	Gastroenterology (1) Oncology (2) Non-disease specific (3) Rheumatology (3)
Patient (representative)	9	Denmark (1) EU perspective (6)* Poland (1) Portugal (1)	Gastroenterology (4) Oncology (2) Non-disease specific (1) Rheumatology (2)
Regulator	7	Denmark (1) EU perspective (5)* Ireland (1)	/
**Representing participants from European organizations or institutions (e.g. representatives of European stakeholder associations). Regulators involved in biosimilar regulatory activities on a European level (i.e. members of a European Medicines Agency committee and/or working party, such as the Biosimilar Medicinal Products Working Party), are included in this category*			
Participants with a pan-European perspective often also provided (home) country specific insights and/or examples in addition to their pan-European perspective			
EU: European, IBD: inflammatory bowel disease, N: number, UK: United Kingdom			